Welcome to our dedicated page for Omnicell Com SEC filings (Ticker: OMCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Omnicell, Inc. filings document financial results, guidance updates, governance matters, and capital-plan items for a Nasdaq-listed healthcare technology company focused on medication management. Form 8-K reports furnish quarterly and annual operating results and record material events such as executive appointments and amendments to bylaws.
Proxy materials describe annual meeting proposals, director elections, executive compensation votes, equity incentive plan authorization, certificate of incorporation amendments, auditor ratification, and related stockholder voting mechanics. These filings also provide formal disclosure around Omnicell’s common stock governance, board oversight, and stockholder rights provisions.
Omnicell, Inc. (OMCL) insider activity disclosure by Brian H. Nutt. The Form 4 shows transactions on 08/15/2025: 681 shares of common stock were disposed of at $31.69 per share to satisfy tax withholding on vested restricted stock units, leaving 9,905 shares beneficially owned by Mr. Nutt. On the same date he purchased 631 shares under the company Employee Stock Purchase Plan at no listed price in this filing, bringing his post-transaction direct ownership to 17,568 shares. The filing also reports a grant of 7,663 restricted stock units that vest 25% on 08/15/2026 and the remaining 75% quarterly over the following three years.